ImmunoCellular Therapeutics Ltd. (IMUC) and Puma Biotechnology Inc. (NASDAQ:PBYI) Comparing side by side

ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) and Puma Biotechnology Inc. (NASDAQ:PBYI), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoCellular Therapeutics Ltd. N/A 0.00 41.80M -0.48 0.00
Puma Biotechnology Inc. 8 -0.02 30.13M -2.61 0.00

Demonstrates ImmunoCellular Therapeutics Ltd. and Puma Biotechnology Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
ImmunoCellular Therapeutics Ltd. 96,535,796,766.74% -321.9% -158.6%
Puma Biotechnology Inc. 378,993,710.69% -245.2% -37.9%

Volatility & Risk

A -0.31 beta means ImmunoCellular Therapeutics Ltd.’s volatility is 131.00% less than Standard & Poor’s 500’s volatility. In other hand, Puma Biotechnology Inc. has beta of 1.69 which is 69.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of ImmunoCellular Therapeutics Ltd. are 9.5 and 9.5 respectively. Its competitor Puma Biotechnology Inc.’s Current Ratio is 2.5 and its Quick Ratio is 2.5. ImmunoCellular Therapeutics Ltd. can pay off short and long-term obligations better than Puma Biotechnology Inc.

Insider & Institutional Ownership

ImmunoCellular Therapeutics Ltd. and Puma Biotechnology Inc. has shares owned by institutional investors as follows: 4.3% and 99.8%. Insiders owned 0.3% of ImmunoCellular Therapeutics Ltd. shares. On the other hand, insiders owned about 11.4% of Puma Biotechnology Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmunoCellular Therapeutics Ltd. 2.46% 47.06% 3.46% -10.71% -89.43% 47.06%
Puma Biotechnology Inc. -0.41% -24.61% -69.24% -64.26% -79.98% -52.58%

For the past year ImmunoCellular Therapeutics Ltd. had bullish trend while Puma Biotechnology Inc. had bearish trend.

Summary

On 7 of the 10 factors ImmunoCellular Therapeutics Ltd. beats Puma Biotechnology Inc.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.